ABT ABBOTT LABORATORIES revenue, earnings and financials

For the quarter ended June 30, 2026, ABBOTT LABORATORIES reported revenue of $12.6B (up 13.0% from a year earlier), net income of $928M and diluted EPS of $0.53; over the last four quarters revenue was $46.6B and net income $5.43B; for the fiscal year ended December 2025 revenue was $44.3B, up 5.7% on the year before.

ABT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $44.3B, gross profit n/a, operating income $8.05B, net income $6.52B (margin 14.7%), EPS $3.72
• Fiscal year ended Dec 2024: revenue $42.0B, gross profit n/a, operating income $6.83B, net income $13.4B (margin 31.9%), EPS $7.64
• Fiscal year ended Dec 2023: revenue $40.1B, gross profit n/a, operating income $6.48B, net income $5.72B (margin 14.3%), EPS $3.26
• Fiscal year ended Dec 2022: revenue $43.7B, gross profit n/a, operating income $8.36B, net income $6.93B (margin 15.9%), EPS $3.91
• Fiscal year ended Dec 2021: revenue $43.1B, gross profit n/a, operating income $8.43B, net income $7.07B (margin 16.4%), EPS $3.94

ABT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $12.6B (up 13.0% year over year), net income $928M, EPS $0.53
• Quarter ended Mar 31, 2026: revenue $11.2B (up 7.8% year over year), net income $1.08B, EPS $0.61
• Quarter ended Dec 31, 2025 (from the annual report): revenue $11.5B (up 4.4% year over year), net income $1.78B, EPS $1.01
• Quarter ended Sep 30, 2025: revenue $11.4B (up 6.9% year over year), net income $1.64B, EPS $0.94
• Quarter ended Jun 30, 2025: revenue $11.1B (up 7.4% year over year), net income $1.78B, EPS $1.01
• Quarter ended Mar 31, 2025: revenue $10.4B (up 4.0% year over year), net income $1.33B, EPS $0.76
• Quarter ended Dec 31, 2024 (from the annual report): revenue $11.0B (up 7.2% year over year), net income $9.23B, EPS $5.26
• Quarter ended Sep 30, 2024: revenue $10.6B (up 4.9% year over year), net income $1.65B, EPS $0.94
• Quarter ended Jun 30, 2024: revenue $10.4B (up 4.0% year over year), net income $1.30B, EPS $0.74
• Quarter ended Mar 31, 2024: revenue $9.96B (up 2.2% year over year), net income $1.23B, EPS $0.70
• Quarter ended Dec 31, 2023 (from the annual report): revenue $10.2B (up 1.5% year over year), net income $1.59B, EPS $0.91
• Quarter ended Sep 30, 2023: revenue $10.1B (down 2.6% year over year), net income $1.44B, EPS $0.82
• Quarter ended Jun 30, 2023: revenue $9.98B (down 11.4% year over year), net income $1.38B, EPS $0.78
• Quarter ended Mar 31, 2023: revenue $9.75B (down 18.1% year over year), net income $1.32B, EPS $0.75
• Quarter ended Dec 31, 2022 (from the annual report): revenue $10.1B (down 12.0% year over year), net income $1.03B, EPS $0.59
• Quarter ended Sep 30, 2022: revenue $10.4B (down 4.7% year over year), net income $1.44B, EPS $0.81
• Quarter ended Jun 30, 2022: revenue $11.3B (up 10.1% year over year), net income $2.02B, EPS $1.14
• Quarter ended Mar 31, 2022: revenue $11.9B (up 13.8% year over year), net income $2.45B, EPS $1.37
• Quarter ended Dec 31, 2021 (from the annual report): revenue $11.5B, net income $1.99B, EPS $1.11
• Quarter ended Sep 30, 2021: revenue $10.9B, net income $2.10B, EPS $1.17

ABT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $9.57B, share buybacks $893M, dividends $2.40 per share
• Fiscal year ended Dec 2024: operating cash flow $8.56B, share buybacks $1.30B, dividends $2.24 per share
• Fiscal year ended Dec 2023: operating cash flow $7.26B, share buybacks $1.23B, dividends $2.08 per share
• Fiscal year ended Dec 2022: operating cash flow $9.58B, share buybacks $3.80B, dividends $1.92 per share
• Fiscal year ended Dec 2021: operating cash flow $10.5B, share buybacks $2.30B

ABT balance sheet

• Jun 30, 2026: cash $5.10B, total assets $109B, total liabilities n/a, shareholders' equity $51.1B, long-term debt $29.6B
• Mar 31, 2026: cash $6.80B, total assets $110B, total liabilities n/a, shareholders' equity $52.1B, long-term debt $29.6B
• Dec 31, 2025: cash $8.52B, total assets $86.7B, total liabilities n/a, shareholders' equity $52.1B, long-term debt $9.90B
• Sep 30, 2025: cash $7.51B, total assets $84.2B, total liabilities n/a, shareholders' equity $51.0B, long-term debt $11.6B
• Jun 30, 2025: cash $6.95B, total assets $84.0B, total liabilities n/a, shareholders' equity $50.6B, long-term debt $12.9B
• Mar 31, 2025: cash $6.53B, total assets $81.4B, total liabilities n/a, shareholders' equity $48.8B, long-term debt $12.7B
• Dec 31, 2024: cash $7.62B, total assets $81.4B, total liabilities n/a, shareholders' equity $47.7B, long-term debt $12.6B
• Sep 30, 2024: cash $7.56B, total assets $74.4B, total liabilities n/a, shareholders' equity $39.8B, long-term debt $12.8B

What is ABT's revenue?

ABBOTT LABORATORIES reported $46.6B of revenue over its last four quarters, through June 30, 2026.

Is ABT profitable?

Yes. ABBOTT LABORATORIES earned $5.43B over the last four quarters.

What is ABT's EPS?

Diluted earnings per share over the last four quarters were $3.09; $0.53 in the latest quarter.

Does ABT pay a dividend?

ABBOTT LABORATORIES paid $2.40 per share in dividends in the fiscal year ended December 2025.

ABT ownership and insider trades · All stocks